The global IBD (ulcerative colitis & Cohn’s disease) treatment market was valued at US$ 17.3 Bn in 2021 and it is projected to grow at a CAGR of 6.8% from 2022 to 2031. The global IBD (ulcerative colitis & Cohn’s disease) treatment market is anticipated to reach more than US$ 34.22 Bn by 2031.
IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market Introduction
Rise in prevalence of inflammatory bowel disease (IBD) across the globe is driving the global IBD (Ulcerative Colitis & Crohn’s Disease) treatment market. IBD is a group of gastrointestinal inflammatory diseases that primarily comprises ulcerative colitis and Crohn’s disease. Inflammatory bowel diseases cause long-term chronic inflammation of the gastrointestinal (GI) tract without any known cause. Ulcerative colitis disease mostly affects the inner lining of large intestines and causes inflammation and sores in the colon and rectum.
Get Sample Copy of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1473
Ulcerative colitis is a more commonly observed disease than Crohn’s disease. It can affect any part of the gastrointestinal tract, starting from the mouth to the small intestine and anus. Common symptoms of IBD include chronic pain and cramps in the abdomen, persistent diarrhea, occasional rectal bleeding, and fever. The exact cause of inflammatory bowel disease is not well understood, and high prevalence and incidence rates of these diseases have been observed in developed countries.
Innovations in product development, approval of drugs, and rising inclination toward the use of biologic and biosimilar drugs are the factors driving the global IBD treatment market. Growth in sales of IBD drugs through online, retail, and hospital pharmacies is helping companies generate more revenues. For instance, in December 2019, the FDA approved two biosimilars – adalimumab and infliximab – for the treatment of Ulcerative Colitis. Biopharmaceutical companies have made significant investments in R&D activities. Large numbers of pipeline products are in different stages of clinical approvals, which are likely to commercialize during the forecast period.
Read Report Overview @ https://www.transparencymarketresearch.com/inflammatory-bowel-disease.html
Furthermore, high prevalence and incidence of IBD in countries in the West is anticipated to augment the global market. According to a report, around 2.5 million people in the U.S. suffered from inflammatory bowel disease in 2020. The prevalence of IBD among the U.S. population is expected to rise to around 3.5 million by 2030. Similarly, data suggests that the incidence and prevalence of inflammatory bowel diseases [IBD] is still increasing in Europe; around 0.2% of the population of Europe suffered from IBD in 2020.
Superior Efficacy, Safety, and Better Therapeutic Outcomes Augmenting Adoption of TNF Inhibitors
The TNF inhibitors segment is projected to lead the global IBD (ulcerative colitis and Crohn’s disease) treatment market during the forecast period. The segment’s large market share can be ascribed to superior efficacy and safety of drugs in this class in the treatment of IBD, increase in adoption of biologics and biosimilars in countries in the West such as the U.K., France, Germany, and the U.S., and high cost of these drugs. Furthermore, rise in adoption of biologic drugs for the treatment of IBD and high clinical R&D budgets contributed to the TNF inhibitors segment’s large share in 2021.
Get Report Methodology @ https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=1473
TNF inhibitors are used as the second line of treatment when other medications do not work effectively to relieve symptoms of IBD. High adoption of TNF inhibitors owing to promising therapeutic results for the management of IBD, high per capita health care expenditure, and increase in number of hospitalizations can be ascribed to the TNF inhibitors segment’s significant market share in 2021.
High Prevalence and Incidence of Ulcerative Colitis to Drive Demand for IBD Treatment
The ulcerative colitis segment accounted for the largest share of the global market in 2021. The trend is expected to continue during the forecast period. High prevalence and incidence of ulcerative colitis in Europe and North America, increase in awareness about the disease, and rise in number of hospitalization cases of ulcerative colitis are the key factors driving the ulcerative colitis segment.
An article published on NCBI (2020) stated that ulcerative colitis has an incidence of 9 to 20 cases per 100,000 per year. Its prevalence is 156 to 291 cases per 100,000 per year in North America and Europe. Similarly, in Canada, more than 104,000 people are living with ulcerative colitis and nearly 4,500 cases of ulcerative colitis are diagnosed every year. Furthermore, a recent report suggests that 600,000 to 900,000 people in the U.S. have ulcerative colitis.
Availability of Wide Range of Drugs for IBD Propelling Retail Pharmacies Segment
The retail pharmacies segment dominated the global market in terms of market share in 2021 due to the rise in sale of biologic drugs through retail pharmacy chains in the U.S. Biologic drugs accounted for major share of the IBD treatment market in the U.S. in 2021. Easy availability of drugs such as corticosteroids, Aminosalicylates, and biologics at retail pharmacy stores and usage of these drugs, except biologics, as the first line of treatment is propelling the retail pharmacies segment.
Moreover, retail pharmacies are considered the first point of contact for self-medication. In 2019, India had more than 800,000 pharmacies; retail pharmacies are still the dominant medical distribution channel. Hence, presence of a large existing base of retail pharmacy stores in countries such as India, China, the U.S., and Canada is likely to augment the retail pharmacies segment during the forecast period.
Get Custom Research Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1473
Regional Outlook of Global IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market
North America dominated the global IBD (ulcerative colitis and Crohn’s disease) treatment market in 2021. It is projected to gain major market share by the end of 2031. The region’s dominance of the global market can be ascribed to high prevalence and increase in incidence of ulcerative colitis and Crohn’s disease in the U.S. and Canada, well-established healthcare infrastructure, and high risk of lifestyle-related factors. Additionally, strong product pipeline of key players is projected to drive the global IBD (ulcerative colitis and Crohn’s disease) treatment market in the region.
Asia Pacific is projected to be the fastest growing market for IBD (ulcerative colitis and Crohn’s disease) treatment during the forecast period. Japan dominated the IBD treatment market in the region in 2021. The IBD (ulcerative colitis and Crohn’s disease) treatment market in China is anticipated to grow at a high CAGR during the forecast period. The IBD (ulcerative colitis and Crohn’s disease) treatment market in Latin America and Middle East & Africa is likely to expand at a decent CAGR during the forecast period due to the increase in IBD patient pool and rise in focus of manufacturers on the development of novel therapeutics.
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
USA – Canada Toll Free: 866-552-3453